BRISTOL-MYERS SQUIBB COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 43.36 USD | -1.52% |
|
-3.77% | -15.49% |
| Sales 2024 * | 46.04B 3,624B | Sales 2025 * | 46.08B 3,627B | Capitalization | 89.25B 7,025B |
|---|---|---|---|---|---|
| Net income 2024 * | -5.41B -426B | Net income 2025 * | 10.22B 804B | EV / Sales 2024 * | 2.79 x |
| Net Debt 2024 * | 39.31B 3,094B | Net Debt 2025 * | 32.04B 2,522B | EV / Sales 2025 * | 2.63 x |
| P/E ratio 2024 * |
-16.8
x | P/E ratio 2025 * |
8.33
x | Employees | 34,100 |
| Yield 2024 * |
5.46% | Yield 2025 * |
5.74% | Free-Float | 69.27% |
More Fundamentals
* Assessed data
More news
Latest transcript on Bristol-Myers Squibb Company
More recommendations
More press releases
More news
| 1 day | -1.52% | ||
| 1 week | -3.77% | ||
| Current month | -1.32% | ||
| 1 month | -11.76% | ||
| 3 months | -13.04% | ||
| 6 months | -11.33% | ||
| Current year | -15.49% |
1 week
43.31
45.72
1 month
43.3149.56
Current year
43.3155.04
1 year
43.3167.16
3 years
43.3181.44
5 years
42.4881.44
10 years
42.4881.44
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 53 | 31/01/15 | |
David Elkins
DFI | Director of Finance/CFO | 55 | 19/11/19 |
Greg Meyers
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Phyllis Yale
BRD | Director/Board Member | 66 | 19/11/19 |
Peter Arduini
BRD | Director/Board Member | 59 | 31/03/16 |
Derica Rice
BRD | Director/Board Member | 59 | 31/08/20 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 12.97% | 254 M€ | +10.44% | - | |
| 4.99% | 2 M€ | -.--% | ||
| 4.01% | 17 M€ | +8.10% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/05/24 | 43.36 | -1.52% | 10,369,242 |
| 17/05/24 | 44.03 | -0.18% | 15,787,957 |
| 16/05/24 | 44.11 | -0.99% | 15,765,711 |
| 15/05/24 | 44.55 | -0.36% | 14,179,383 |
| 14/05/24 | 44.71 | -0.78% | 14,536,549 |
Delayed Quote Nyse, May 20, 2024 at 09:00 pm
More quotes
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
Pharmaceuticals
Calendar
26/07/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
43.36
USD
Average target price
53.19
USD
Spread / Average Target
+22.68%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -15.49% | 89.25B | |
| +34.35% | 693B | |
| +29.39% | 584B | |
| -3.49% | 372B | |
| +20.15% | 332B | |
| +6.19% | 294B | |
| +14.11% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +9.21% | 168B |
- Stock Market
- Equities
- BMY Stock
